SignalCorporate
Sarepta misses on the bottom line but raises lower end of 2026 revenue guidance
Sarepta misses on the bottom line but raises lower end of 2026 revenue guidance
Context
What happened: Sarepta Therapeutics (SRPT) reported mixed Q3 results, missing on the bottom line but beating on the top. The company also raised the lower end of its full-year revenue guidance range.
Why it matters: The beat on the top line and the higher floor on full-year revenue guidance came alongside the earnings miss, giving a mixed signal on the quarter.
Coverage: 3 outlets in 24h
What changed
Sarepta Therapeutics (SRPT) reported mixed Q3 results, missing on the bottom line but beating on the top. The company also raised the lower end of its full-year revenue guidance range.
Why it matters
The beat on the top line and the higher floor on full-year revenue guidance came alongside the earnings miss, giving a mixed signal on the quarter.